Company Overview and News

 
No plans to divest stake in DNeX — Censof

2018-09-06 theedgemarkets
KUALA LUMPUR: Censof Holdings Bhd has no plans to divest its 16.22% stake in Dagang NeXchange Bhd (DNeX) as crude oil prices continue to gain strength.
4456 5195

 
7-Eleven, Affin Bank, Gabungan AQRS, Hengyuan, XOX, Nylex, Ancom, Utusan, Globaltec, Censof and DNeX

2018-09-05 theedgemarkets
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 6) may include: 7-Eleven Malaysia Holdings Bhd, Affin Bank Bhd, Gabungan AQRS Bhd, Hengyuan Refining Co Bhd, XOX Bhd, Nylex (Malaysia) Bhd, Ancom Bhd, Utusan Melayu (Malaysia) Bhd, Globaltec Formation Bhd, Censof Holdings Bhd and Dagang NeXchange Bhd (DNeX).
5226 5754 4456 PSKXF 5220 PHSXY PSE BCOR 5195

 
Censof says no plans to divest DNeX stake

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): Censof Holdings Bhd has no plans to divest its estimated 16% stake in Dagang NeXchange Bhd (DNeX) as Censof expects DNeX to pay dividends amid rising crude oil prices.
4456 5195

 
Century Software secures DBKL and Socso contracts

2018-08-24 malaymail
KUALA LUMPUR, Aug 24 — Century Software (M) Sdn Bhd, a wholly-owned subsidiary of Censof Holdings Bhd (Censof), has secured a RM3.85 million contract from Kuala Lumpur City Hall (DBKL) to provide comprehensive maintenance and support services for its ePBT financial management system.
5195

 
Sime Darby Plantation, Axiata Group Bhd, Malakoff, Pestech, Censof, Hibiscus, S P Setia, Maybulk, MPI and Tropicana

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): Based on corporate announcements and news flow today, companies that will be in focus on Friday (Aug 24) may include: Sime Darby Plantation Bhd, Axiata Group Bhd, Malakoff Corp Bhd, Pestech International Bhd, Censof Holdings Bhd, Hibiscus Petroleum Bhd, S P Setia Bhd, Malaysian Bulk Carriers Bhd, Malaysian Pacific Industries Bhd and Tropicana Corp Bhd.
5347 3867 6888 TNABY 5219 5077 8664 AXXTF TNABF 5195 HIPEF 5199

 
Censof bags RM3.85m maintenance and support services job from DBKL

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): Censof Holdings Bhd has bagged a RM3.85 million contract from Kuala Lumpur City Hall (DBKL) to undertake a comprehensive maintenance and support services of ePBT financial management system for a tenure of 12 months.
5195 BSMAF 1818

4
Censof says Erwin Selvarajah is now a substantial shareholder

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): Censof Holdings Bhd said today that Erwin Selvarajah has emerged as a substantial shareholder in the financial management software solutions provider, after he raised his stake to 5.1% in the company.
5195 BSMAF 1818

 
Trading ideas: Luxchem, Lotte Chemical, Yinson, Censof, Bintulu Port

2018-05-02 thestar.com.my
KUALA LUMPUR: Luxchem Corp Bhd , Lotte Chemical Titan Holding Bhd, Yinson Holdings Bhd , Censof Holdings Bhd and Bintulu Port Holdings Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
7293 7206 5032 5195

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...